ATLAS News · Deals

Pfizer Gets Global Rights to Three Starna In Vivo CAR-T Therapies

· 1 sources

Pfizer secures rights outside Greater China to three preclinical in vivo CAR-T therapies from Starna Therapeutics, MedCity News reports.

What happened

Pfizer has obtained global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics, MedCity News reports. The deal extends Pfizer's immunology strategy into in vivo cell therapy.

According to MedCity News, the three therapies are in preclinical development and target autoimmune diseases that have not been disclosed. The outlet describes the agreement as the latest in a series of large pharmaceutical deals involving in vivo cell therapy assets and platform technologies.

Context

In vivo CAR-T approaches aim to engineer immune cells inside the patient's body rather than modifying them outside it first.

Why it matters

The deal shows how a large drugmaker like Pfizer is positioning in the growing field of in vivo cell therapy for autoimmune conditions.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

PfizerPFE

−1.44%

Healthcare · NYSE

Live price
$28.06▼ -1.44%

live price · USD

Close on November 18
$28.06−1.44% vs. previous close ($28.47)
Fair value (ATLAS)
$36.82Fair range: $29.63 to $70.73The price ($28.06) is 23.8% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $27.06 and $29.31; 9 in 10, between $25.21 and $31.46.
See the full ATLAS analysis of Pfizer →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

  1. Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal · MedCity News · November 18, 2026

Related

Latest market news · Markets today on ATLAS · Pfizer

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy